BPC-157: What the Published Research Covers, and Where It Stops
Marketing copy for BPC-157 often runs well ahead of the science. The papers themselves ask a narrower set of questions, almost all of them in animals. This overview starts with the caveats, because they shape how every finding below should be read, and then walks through the three main research threads.
Three caveats to keep in mind
- The data are rodent data. Nearly every study used rats or mice. Efficacy for any indication has not been established by a single published, peer-reviewed human clinical trial.
- The citations cluster. Much of the literature traces back to a small number of research groups. Independent replication at scale is therefore thinner than a raw count of papers would suggest.
- It is unapproved. No country has approved BPC-157 for use in people, and anti-doping bodies list it as a prohibited unapproved substance.
Thread one: the gut lining
The earliest BPC-157 work was gastrointestinal, and that remains the most widely replicated part of the literature. In rodents, researchers tested whether it protects gastric and intestinal mucosa from damage caused by NSAIDs or by alcohol. They also studied healing of anastomoses and models of inflammatory bowel injury.
Thread two: vessels and nitric oxide
A number of groups have described more capillary formation and raised VEGF expression in injured tissue, alongside interactions with the NO pathway. Rather than being a separate phenomenon, this vascular activity may be what drives the healing results in the other two threads.
Thread three: tendon, ligament and muscle
This is where most of the papers sit. Using transection and crush injuries in rodents, investigators compared treated animals with controls and reported faster migration and outgrowth of fibroblasts, collagen that was laid down in a more orderly way, and quicker return of function. Cell work with tendon fibroblasts implicates the FAK–paxillin pathway in the migration effect.
The molecule behind the name
“BPC” is short for Body Protection Compound. The peptide is synthetic, a pentadecapeptide of fifteen residues weighing about 1419 Da, and its sequence was taken from a fragment of a protective protein identified in human gastric juice. Most peptides fall apart in acid; BPC-157 is unusually resistant, which helped make it a favored tool in gut research. Nowhere is it an approved drug, and any material sold under the name is research-grade chemical synthesis.
Handling in the lab
It goes into bacteriostatic water without trouble and is notably robust for a peptide. Even so, keep the solution in the fridge after reconstitution, shield it from light, and compare identity and purity with the certificate of analysis for your batch.
BPC-157 at LiliPeptide
This store lists BPC-157 in 5mg, 10mg and 20mg. The compound also appears in three multi-compound listings: the BPC-157 + TB-500 Blend (10mg, 20mg), GLOW (GHK-Cu + TB-500 + BPC-157) at 70mg and KLOW (GHK-Cu + TB-500 + BPC-157 + KPV) at 80mg.
Our COAs page links one Freedom Diagnostics Testing report for this compound: BPC-157 10mg, batch LIL8032026BLU, tested 23 Sep 2026, report LILI2609210553. That report applies only to the sample it names. The page has no report for the 5mg or 20mg options, or for any of the blends.
The BPC-157 and TB-500 comparison explains how the two compounds differ. For research use only. Not for human or veterinary use.
